ArticleScientific reports2025
Functional improvements correlate with enhanced quality of life following mesenchymal stromal cell therapy in chronic spinal cord injury.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Redefining clinically meaningful improvement in traumatic cervical spinal cord injury: a participant-centered perspective from community feedback sessions.Spinal cord · 2026Review
- Best Evidence Summary for Evidence-Based Nursing Self-Management in Patients with Neurogenic Bladder Following Spinal Cord Injury.Patient preference and adherence · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stromal cell (MSC) therapy is an emerging promising treatment for spinal cord injury (SCI) management. However, and even though sensory and motor evaluations of this treatment are being reported, there is a deficiency in reporting standardized evaluation of the Quality of Life (QoL) measures, especially as it relates to bowel/bladder control in patients. Subtle enhancements in these functions, even though undetectable by routine examination and clinical assessments, may have a significant impact on patients' perceived well-being. In this study, we specifically examine how MSC therapy affected self-reported QoL of measures of SCI patients. A prospective analysis was conducted on 20 chronic SCI patients receiving MSC therapy [bone marrow (BM) or Wharton's jelly (WJ) derived]. Bowel function was assessed using the Neurogenic Bowel Dysfunction Score (NBDS) and Wexner Score, while bladder function and QoL were evaluated via the modified King's Health instrument and WHOQOL-BREF. Follow-up extended for one-year post-treatment. Both BM- and WJ-MSC groups showed progressive improvement in bowel/bladder function, with significant declines in NBDS (P < 0.05) and Wexner scores (P < 0.001). QoL domains (physical, psychological, social, environmental) improved significantly (P < 0.05), with environmental QoL scoring highest in BM-MSC recipients. Bladder control improved in sensory perception but not continence, concurring with prior findings. Our results show that MSC therapy enhances bowel/bladder function and QoL in chronic SCI patients, though individualized assessment tools are essential to capture subtle improvements. These results support MSC therapy as a promising intervention, warranting further long-term studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.